Skip to main content
Premium Trial:

Request an Annual Quote

'High-priced Poker Game'

GlaxoSmithKline has made a $2.6 billion unsolicited offer to take over Human Genome Sciences, reports Brett Chase at Miyanville. But not only has Human Genome rejected Glaxo's offer, it put itself up for sale to the highest bidder, saying Glaxo's offer of $13 a share is too low and doesn't reflect the potential value of the company.

"This potential marriage has been speculated for years," Chase says. "The two companies have significant stakes in each other. Glaxo co-developed the lupus drug Benlysta, which was approved last year. The companies are in the late stages of developing a drug for heart disease (darapladib) and a diabetes treatment (albiglutide)."

Analysts tell Chase that in the end, Glaxo will probably buy Human Genome, but that the bidding war will drive the price higher. "If anything, it's a high-priced poker game," Chase says. "Expect Glaxo to win."

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.